NEWS & EVENTS
EIT Health Catapult
We are excited to share that Fusix Biotech was selected to compete in the semi-finals of the 9th edition of EIT Health Catapult. Each year, the competition showcases Europe’s most promising life science and healthtech start-ups to leading experts and investors. The Catapult programme has supported over 330 companies in the eight editions so far, with many closing multi-million investment rounds of euros after participating. Participants often highlight that the EIT Health Catapult flagship programme, where[...]
Merck Advance Biotech Grant
We are excited to share that Fusix Biotech is the winner of the 2023 Merck Advance Biotech Grant. Fusix Biotech GmbH Biotech led by Dr. Jennifer Altomonte took home the first price, showcasing groundbreaking work that captivated everyone present. Merck understands the challenges emerging biotech companies face in the quest to push the next generation of drugs to market. This is why they have developed the Advance Biotech Grant programs which occurs on regular basis[...]
BlueYard × Nucleate Partnership Announcing the 2023 Venture Prize Winners
We are excited to share that Fusix Biotech is one of winners of the 2023 Nucleate Venture Prize funded by BlueYard Capital. BlueYard’s strategy around biology is based on the premise that humankind’s ability to engineer and understand biology will not only fundamentally transform how we diagnose, treat, and manage disease, but also reinvent how we produce new materials and the food required to support human life and sustain our planet. In recognition of these[...]
Science4Life Venture Cup 2022
In the Science4Life Venture Cup, Fusix Biotech from Munich convinced the jury. The start-up took third place with its idea of offering patients with difficult-to-treat cancers safe and effective immunotherapeutic therapy approaches with the help of a platform technology. For the first time since 2019, the final awards ceremony of the Science4Life Venture Cup and Science4Life Energy Cup of the independent start-up initiative Science4Life e.V. was once again able to take place on a grand[...]
Phase 1: Munich Business Plan Competition
We are excited to share that Fusix Biotech is one of winners of the Munich Business Plan competition organized by BayStartUP. Phase 1 is focused on the idea and competitive opportunity. Thanks to BayStartUP and all the jurors for the support. The Munich Business Plan Competition is one of the most prestigious awards that startups can receive for innovative business concepts in Germany. The winners are characterized by a very good understanding of the market[...]
10th BioAngels Virtual Pitch
We are grateful for the chance to present at BioM's BioAngels event in front of venture capital investors, business angels and other private investors who invest in life sciences & health tech start-ups. BioAngels is BioM’s exclusive matchmaking event for venture capital investors, business angels and other private investors who invest in life sciences & health tech start-ups. As usual, BioM prepared the founders for their virtual pitch in a separate training session. The aim[...]
Fighting Cancer with Viruses
TUM Faszination Forschung: At the Klinikum rechts der Isar, researchers hope to harness the lethal power of viruses to combat malignant tumors. Jennifer Altomonte and her team are engineering viruses to optimize their therapeutic potential in cancer cells. Part of this therapy concept involves mobilizing specific immune cells. This makes use of a phenomenon that goes hand in hand with viral infection, namely that when pathogens multiply in tumor tissue and destroy it, the dying[...]
m4 Award 2019
We are proud to announce that PD Dr. Jennifer Altomonte and Dr. Teresa Krabbe from the Klinikum rechts der Isar at the Technical University of Munich have been awarded the M4 Award 2019 for the "Commercialization of oncolytic viruses (Fusix Biotech)". Oncolytic viruses (OVs) now claim a steadily growing market share in cancer therapeutics. These viruses offer an elegant and multimodal mode of action that enables a long-lasting systemic therapeutic success. Despite great progress, oncolytic[...]
